Cambridge, MA (September 5, 2012) – MedCap Advisors, the mergers & acquisition and strategic consulting firm specializing in medical technology, today announced it has appointed Edward Ahn, Ph. D., as Managing Director and Chief Science Officer. Dr. Ahn is a leading expert in the development and commercialization of biomaterials nanotechnology, with over 10 years of industrial and academic experience.
“We are extremely fortunate to have a professional of Edward's caliber join our firm,” said Mr. Christopher Velis, CEO of MedCap Advisors. “His expertise is perfectly in tune with our mission to improve health and medical technology, as we stay focused on the intersection at which physicians and patients meet. Ed will be a significant contributor to our team and to our clients.”
Dr. Ahn most recently served as Vice President of Biologics Product Development for Pioneer® Surgical Technology, Inc. and its newly formed biologics division. He successfully developed and launched novel synthetic bone grafts, allograft-based tissue products and structural calcium phosphate nanotechnology in interbody spinal fusion.
In 2001, Dr. Ahn won the Grand Prize in the MIT $50k Business Plan Competition and subsequently used his thesis to found Angstrom Medica, a company focused on commercializing nanotechnology in orthopedics. Here he achieved the first nanomedical device approved by the FDA in 2005; the company was subsequently acquired by Pioneer® Surgical Technology, Inc.
Dr. Ahn earned his B.S.in Chemical Engineering from Stanford University and M.S. in Chemical Engineering Practice and Ph.D. in Chemical Engineering from MIT. Presently he is a senior lecturer at Harvard University's School of Engineering and Applied Science, and is the Vice-Chairman of the MIT Enterprise Forum of Cambridge. He is also a member of the Scientific Advisory Board of the Center of Innovation for Nanobiotechnology (COIN) and a principal of First Founders, Ltd., a not-for-profit corporation dedicated to building young business ventures emerging from academic and other institutional research.
This announcement also follows on the news of MedCap’s move to larger space in Harvard Square in Cambridge.